1. Home
  2. News
  3. Imugene Ltd
  4. Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
More Imugene Ltd news
Imugene LtdASX: IMU

Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial

Dec 16, 2020 at 10:25 PM EST · Issued by Imugene Ltd

Filed with ASX · Dec 16, 2020 at 10:25 PM EST · 2 pages · English

On 6ix: 6ix.com/news/imugene-enrols-first-cohort-of-pd1-vaxx-clinical-trial

Imugene Ltd on 6ix

Story so far

  • Imugene First Patient Dosed in PD1-VAXX Clinical TrialDec 1, 2020
  • CF33 Oncolytic Virus Clinical Trial Program UpdateOct 21, 2019
  • IMU Meets Investigator for Gastric Cancer Clinical TrialFeb 9, 2018

Earlier from Imugene

  • Imugene Receives $4.82 million R&D Tax IncentiveDec 10, 2020
  • Imugene First Patient Dosed in PD1-VAXX Clinical TrialNov 30, 2020
  • Imugene HER Vaxx shows positive Overall Survival in trialNov 22, 2020
  • Imugene Receives FDA IND Approval for PD1-VAXX Trial in USANov 1, 2020
  • Imugene Immunotherapy Combination Patent Granted in USOct 1, 2020

Later from Imugene

  • Imugene completes recruitment to HER-Vaxx Phase 2 trialimJan 6, 2021
  • Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical TrialJan 20, 2021
  • Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX TrialFeb 11, 2021
  • Imugene to Present HER-Vaxx Phase 2 Data at AACR21 MeetingMar 10, 2021
  • S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer